IBJNews

Q&A

Back to TopCommentsE-mailPrintBookmark and Share

Mike Sherman, the chief financial officer at West Lafayette-based Endocyte Inc., talked about how the drug firm’s funding partnership with New Jersey-based Merck & Co. Inc. has helped accelerate the company’s pipeline. Endocyte, which employs 80 people, including about 15 in Indianapolis, has applied with European regulators to bring its first drug, vintafolide, to market to treat ovarian cancer. Endocyte is using the same technology that lies behind vintafolide to develop drugs to treat cancers of the lung, breast and prostate.

IBJ: How has your partnership with Merck changed Endocyte’s operations?

A: It brought us not only this financial flexibility. It also brought us an immediate commercial presence on a global basis. Put simply, our financial situation has changed and that has allowed us to do things to accelerate the pipeline. To bring those [drugs] along more quickly is very important to our creating value and our ability to help patients. Had we not done the partnership with Merck, we would have had to move forward on those compounds much less quickly. We were able to accelerate those things by two to three years over what we would have been able to do.

IBJ: Merck recently committed to fund 75 percent of a possible new study of vintafolide and to fund clinical trials of Endocyte's breast cancer drug. What does that say about Endocyte’s potential for commercializing more than one drug?

A: We have been very pleased with not only the level of collaboration, the frequency of collaboration, but also the depth of it. We are really intertwined and attached at the hip on all aspects of the business. Endocyte is a true platform company, a technology that is highly leverageable into not only new therapeutics but new therapeutics with companion diagnostics. [Most of Endocyte’s drugs use an imaging agent that helps identify patients who can benefit from its drugs.]

IBJ: Endocyte expects to hear from European regulators on whether they will OK vintafolide and its companion imaging agent for sale by the end of this year. If it wins approval, Merck will spearhead sales of the drug while Endocyte will build out a sales team for the imaging agent. What impact, if any, will those events have on your Indiana operations?

A: I would expect the Indianapolis office to continue to grow. We’ll keep our science and technical-related positions in West Lafayette. West Lafayette will always be the headquarters, at least for the foreseeable future. But as we bring on commercial activities, they’ll be added at the Indianapolis office. We will be establishing an office in Switzerland that will be our European headquarters.

 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. The east side does have potential...and I have always thought Washington Scare should become an outlet mall. Anyone remember how popular Eastgate was? Well, Indy has no outlet malls, we have to go to Edinburgh for the deep discounts and I don't understand why. Jim is right. We need a few good eastsiders interested in actually making some noise and trying to change the commerce, culture and stereotypes of the East side. Irvington is very progressive and making great strides, why can't the far east side ride on their coat tails to make some changes?

  2. Boston.com has an article from 2010 where they talk about how Interactions moved to Massachusetts in the year prior. http://www.boston.com/business/technology/innoeco/2010/07/interactions_banks_63_million.html The article includes a link back to that Inside Indiana Business press release I linked to earlier, snarkily noting, "Guess this 2006 plan to create 200-plus new jobs in Indiana didn't exactly work out."

  3. I live on the east side and I have read all your comments. a local paper just did an article on Washington square mall with just as many comments and concerns. I am not sure if they are still around, but there was an east side coalition with good intentions to do good things on the east side. And there is a facebook post that called my eastside indy with many old members of the eastside who voice concerns about the east side of the city. We need to come together and not just complain and moan, but come up with actual concrete solutions, because what Dal said is very very true- the eastside could be a goldmine in the right hands. But if anyone is going damn, and change things, it is us eastside residents

  4. Please go back re-read your economics text book and the fine print on the February 2014 CBO report. A minimum wage increase has never resulted in a net job loss...

  5. The GOP at the Statehouse is more interested in PR to keep their majority, than using it to get anything good actually done. The State continues its downward spiral.

ADVERTISEMENT